{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:57:44Z","timestamp":1790225864028,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.revmed.2019.03.333","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T11:47:22Z","timestamp":1554983242000},"page":"590-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Infection par le virus de l\u2019h\u00e9patite B\u00a0: histoire naturelle, manifestations cliniques et principes th\u00e9rapeutiques"],"prefix":"10.1016","volume":"40","author":[{"given":"O.","family":"Paccoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Surgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2019.03.333_bib0340","article-title":"World Health Organization","author":"World Health Organization","year":"2017","journal-title":"Global Hepatitis Programme. Global hepatitis report, 2017 [Internet]."},{"key":"10.1016\/j.revmed.2019.03.333_bib0345","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.03.333_bib0350","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cld.2016.06.006","article-title":"Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease","volume":"20","author":"Nelson","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.revmed.2019.03.333_bib0675","series-title":"Prise en charge des personnes infect\u00e9es par les virus de l\u2019h\u00e9patite B ou de l\u2019h\u00e9patite C. Rapport de recommandations 2014 sous la direction du Pr Daniel Dhumeaux et sous l\u2019\u00e9gide de l\u2019ANRS et de l\u2019AFEF","year":"2014"},{"issue":"11","key":"10.1016\/j.revmed.2019.03.333_bib0680","first-page":"188","article-title":"D\u00e9pistage des h\u00e9patites B et C en France en 2016, nouvelle \u00e9dition de l\u2019enqu\u00eate LaboHep","author":"Pioche","year":"2018","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.revmed.2019.03.333_bib0365","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S1473-3099(18)30117-8","article-title":"How effective are approaches to migrant screening for infectious diseases in Europe?. A systematic review","volume":"18","author":"Seedat","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.revmed.2019.03.333_bib0370","doi-asserted-by":"crossref","first-page":"e14461","DOI":"10.1371\/journal.pone.0044611","article-title":"Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis","volume":"7","author":"Rossi","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.revmed.2019.03.333_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.me.32.020181.000245","article-title":"Serologic markers of hepatitis B virus infection","volume":"32","author":"Hoofnagle","year":"1981","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.revmed.2019.03.333_bib0380","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","article-title":"Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state","volume":"151","author":"McMahon","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.revmed.2019.03.333_bib0385","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.03.333_bib0390","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.revmed.2019.03.333_bib0395","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0168-8278(02)00004-1","article-title":"Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers","volume":"36","author":"Martinot-Peignoux","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0400","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0405","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.revmed.2019.03.333_bib0410","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3350\/cmh.2016.0045","article-title":"The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy","volume":"22","author":"Varbobitis","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0415","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.revmed.2010.08.013","article-title":"[Hepatitis B virus, extrahepatic immunologic manifestations and risk of viral reactivation]","volume":"32","author":"Terrier","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2019.03.333_bib0420","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jhep.2005.05.029","article-title":"Hepatitis B virus genotypes and extrahepatic manifestations","volume":"43","author":"Cacoub","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0425","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","article-title":"Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients","volume":"84","author":"Guillevin","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2019.03.333_bib0430","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/liv.13498","article-title":"Spectrum of hepatitis B and renal involvement","volume":"38","author":"Shah","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.revmed.2019.03.333_bib0435","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.rdc.2009.03.006","article-title":"Hepatitis B-related autoimmune manifestations","volume":"35","author":"Cacoub","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.revmed.2019.03.333_bib0440","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0022-510X(87)90123-7","article-title":"Demyelinating neuropathy associated with hepatitis B virus infection. Detection of immune complexes composed of hepatitis B virus surface antigen","volume":"77","author":"Tsukada","year":"1987","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.revmed.2019.03.333_bib0445","first-page":"254","article-title":"Nonspecific immune parameters and hepatitis B antigens in patients with uveitis","volume":"16","author":"Grob","year":"1976","journal-title":"Mod Probl Ophthalmol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0450","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00004836-199507000-00011","article-title":"Chronic leukocytoclastic vasculitis complicating HBV infection. Possible role of mutant forms of HBV in pathogenesis and persistence of disease","volume":"21","author":"Bonkovsky","year":"1995","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0455","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1468-3083.2004.01185.x","article-title":"Dermatological manifestations in hepatitis B surface antigen carriers in east region of Turkey","volume":"19","author":"Dogan","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0460","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0465","article-title":"Global Hepatitis Programme","author":"World Health Organization","year":"2015","journal-title":"Guidelines for the prevention, care, and treatment of persons with chronic hepatitis B infection [Internet]"},{"key":"10.1016\/j.revmed.2019.03.333_bib0470","doi-asserted-by":"crossref","first-page":"e04493","DOI":"10.1371\/journal.pone.0044930","article-title":"Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis","volume":"7","author":"Chon","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.revmed.2019.03.333_bib0475","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"European Association for Study of Liver","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0480","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","article-title":"Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma","volume":"46","author":"Lin","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0485","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2019.03.333_bib0490","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.03.333_bib0495","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/gutjnl-2013-306409","article-title":"Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease","volume":"63","author":"Cho","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2019.03.333_bib0500","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0505","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0510","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2012.01.044","article-title":"Effectiveness of hepatitis B treatment in clinical practice","volume":"142","author":"Scaglione","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0515","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0520","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0525","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21486","article-title":"A randomized controlled trial of lamivudine to treat acute hepatitis B","volume":"45","author":"Kumar","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0530","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/gast.2001.24839","article-title":"Management of hepatitis B: 2000--summary of a workshop","volume":"120","author":"Lok","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0535","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0540","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.333_bib0545","doi-asserted-by":"crossref","DOI":"10.3390\/v9030056","article-title":"Complete and Incomplete Hepatitis B Virus Particles: Formation Function, and Application","volume":"9","author":"Hu","year":"2017","journal-title":"Viruses"},{"issue":"1 Suppl","key":"10.1016\/j.revmed.2019.03.333_bib0550","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","article-title":"New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus","volume":"64","author":"Durantel","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0555","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0560","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0140-6736(77)91995-X","article-title":"Reactivation of hepatitis b after transplantation operations","volume":"1","author":"Nagington","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.03.333_bib0565","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(75)90897-1","article-title":"Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy","volume":"2","author":"Galbraith","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.03.333_bib0570","doi-asserted-by":"crossref","first-page":"e0126037","DOI":"10.1371\/journal.pone.0126037","article-title":"High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.revmed.2019.03.333_bib0575","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0580","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study","volume":"70","author":"Yeo","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0585","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.revmed.2019.03.333_bib0590","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3350\/cmh.2016.0024","article-title":"Prevention of Hepatitis B reactivation in the setting of immunosuppression","volume":"22","author":"Pattullo","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0595","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00277-012-1405-6","article-title":"Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy","volume":"91","author":"Pei","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0600","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0605","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.revmed.2019.03.333_bib0610","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.revmed.2019.03.333_bib0615","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1440-1843.2010.01798.x","article-title":"Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids","volume":"15","author":"Kim","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0620","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2019.03.333_bib0625","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jhep.2014.10.008","article-title":"Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach","volume":"62","author":"Lemoine","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0630","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0140-6736(16)31144-8","article-title":"Towards elimination of viral hepatitis by 2030","volume":"388","author":"The Lancet null","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.03.333_bib0635","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3201\/eid2305.161477","article-title":"Prevention of chronic hepatitis b after 3 decades of escalating vaccination policy","volume":"23","author":"Cui","year":"2017","journal-title":"China. Emerging Infect Dis"},{"key":"10.1016\/j.revmed.2019.03.333_bib0640","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","article-title":"Long-term effects of Hepatitis B immunization of infants in preventing liver cancer","volume":"151","author":"Chang","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2019.03.333_bib0645","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent Hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2019.03.333_bib0650","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir versus placebo to prevent perinatal transmission of hepatitis B","volume":"378","author":"Jourdain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2019.03.333_bib0655","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jvh.12827","article-title":"Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings","volume":"25","author":"Duchesne","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.revmed.2019.03.333_bib0660","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2018.05.024","article-title":"Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa","volume":"69","author":"Shimakawa","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2019.03.333_bib0665","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2214-109X(16)30101-2","article-title":"Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis","volume":"4","author":"Nayagam","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.revmed.2019.03.333_bib0670","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2018.10.048","article-title":"What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C\u00a0Virus as Global Health Threats?","volume":"156","author":"Ward","year":"2019","journal-title":"Gastroenterology"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631930428X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631930428X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:41:39Z","timestamp":1759336899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886631930428X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S024886631930428X"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2019.03.333","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infection par le virus de l\u2019h\u00e9patite B\u00a0: histoire naturelle, manifestations cliniques et principes th\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2019.03.333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}